Jefferies Healthcare Conference
June 5, 2024
New York
Downloads
- Pressemitteilung
- Präsentation (Englischsprachig)
- Transkript (Englischsprachig)
Goldman Sachs 45th Annual Global Healthcare Conference
June 12, 2024
Miami
Downloads
- Pressemitteilung
- Präsentation (Englischsprachig)
- Transkript (Englischsprachig)
Past events
Annual General Meeting of Shareholders
June 22, 2022
Amsterdam
Downloads
- Pressemitteilung
- Präsentation (Englischsprachig)
- Transkript (Englischsprachig)
The JMP Securities Life Sciences Conference
June 15, 2022
New York
Downloads
- Pressemitteilung
- Präsentation (Englischsprachig)
- Transkript (Englischsprachig)
Jefferies Healthcare Conference
June 9, 2022
New York
Downloads
- Pressemitteilung
- Präsentation (Englischsprachig)
- Transkript (Englischsprachig)
Links
UBS – 2022 Global Healthcare Conference
June 1, 2022
Virtual
Downloads
- Pressemitteilung
- Präsentation (Englischsprachig)
- Transkript (Englischsprachig)
Links
BofA Securities 2022 Healthcare Conference
May 10, 2022
Las Vegas
Downloads
- Pressemitteilung
- Präsentation (Englischsprachig)
- Transkript (Englischsprachig)
Links
Fourth Quarter and Full-Year 2021 Financial Results and Business Updates – Conference Call & Webcast
April 28, 2022
CureVac N.V. (Nasdaq: CVAC) has reported financial results, and provided business updates for the fourth quarter and full-year 2021 on Thursday, April 28, 2022. On the same day, the company hosted a conference call and webcast.
Please find the corresponding press release and presentation slides below. An archived webcast will also be made available through the same link on the CureVac website shortly.
Downloads
Links
Conference Call & Webcast: Third Quarter and First Nine Months 2021 Financial Results and Business Updates
November 19, 2021
CureVac N.V. (Nasdaq: CVAC) reported financial results and business updates for the third quarter and first nine months of 2021 on Friday, November 19, 2021. The company hosted a conference call and webcast on the same day at 2:00 p.m. CET / 08:00 a.m. EST.
Please find the corresponding press release, presentation slides, transcript and the archived webcast below.
Downloads
Links
9th International mRNA Health Conference
November 09 - 10, 2021
Hybrid event on-site in Berlin, Germany, and online via virtual platform
Conference Call & Webcast: Focus Shift to Second-Generation mRNA Technology
October 12, 2021
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced on Tuesday, October 12, 2021 the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).
The company hosted a conference call and webcast on the same day at 03:00 p.m. CEST / 09:00 a.m. EST.
Please find the corresponding press release, presentation slides, transcript as well as an archived webcast below.
Downloads
Links
Press Conference: Focus Shift to Second-Generation mRNA Technology (German language)
October 12, 2021
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced on Tuesday, October 12, 2021 the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).
The company hosted a German speaking press conference on the same day at 02:00 p.m. CEST / 08:00 a.m. EST.
Please find the corresponding press release, presentation slides and archived webcast below.
Downloads
- Press Release
- Presentation (German only)
Links
- Replay Press Conference (German language)
Final Analysis of Phase 2b/3 Clinical Trial for CVnCoV – Webcast & Conference Call
July 1, 2021
On Wednesday, June 30, 2021, CureVac N.V. (Nasdaq: CVAC) announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.
The company hosted a conference call and webcast on Thursday, July 1, 2021, 2:00 p.m. CET / 8:00 a.m. EDT.
A replay of the webcast can be found under "Links".
Downloads
Links